|
REDEFINE-4 Results: What They Mean for Patients
|
Written by: J. Smith |
Hits: 177
|
|
Novo Nordisk Renames Oral Semaglutide as Ozempic Pill Ahead of U.S. Launch
|
Written by: J. Smith |
Hits: 218
|
|
Wegovy Oral Pill Launches in United States
|
Written by: J. Smith |
Hits: 325
|
|
FDA Approves First Oral GLP-1 for Chronic Weight Management
|
Written by: J. Smith |
Hits: 335
|
|
Retatrutide Delivers Phase 3 Success and Signals Lilly’s Strategic Positioning
|
Written by: J. Smith |
Hits: 667
|
|
Novo Nordisk Seeks FDA Approval for Higher 7.2 mg Dose of Wegovy
|
Written by: J. Smith |
Hits: 311
|
|
Novo Nordisk Reports Strong Phase 2 Results for Amycretin in Type 2 Diabetes
|
Written by: J. Smith |
Hits: 324
|
|
Oral Semaglutide Does Not Slow Alzheimer’s Progression: How Today’s Results Fit the Larger Story
|
Written by: J. Smith |
Hits: 339
|
|
Zealand Pharma Pauses Development of Dapiglutide
|
Written by: J. Smith |
Hits: 400
|
|
Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
|
Written by: J. Smith |
Hits: 221
|
